Carbogen Amcis joins the Analgesia Partnership cluster

BUBENDORF, SWITZERLAND: Carbogen Amcis, a pharmaceutical process development and active pharmaceutical ingredient (API) manufacturing company, has joint the cluster of excellence Analgesia Partnership. The Analgesia Partnership cluster promotes the collaboration among academia and established industry leaders involved in the discovery and the chemical/clinical development of new innovative analgesic drugs.

As a new member, Carbogen Amcis will bring to the cluster of excellence a long-standing expertise in the development of aseptic drugs backed up by in-house pre-formulation, formulation and manufacturing capabilities. As part of the platform of services of Analgesia Partnership, Carbogen Amcis will provide additional core competences such as the formulation of new drug products, the development of lyophilization cycles and the fast supply of batches for pre-clinical and clinical studies.

“We are delighted to be part of the Analgesia Partnership cluster and to provide our competences to this one of a kind platform in pain innovation. We are looking forward to contributing to the future achievements of the cluster in the field of pain management by sharing our expertise in the development and cGMP manufacturing of API and drug products,” said Maxime Laugier, Director, Pharmaceutical Development and Projects, Carbogen Amcis.

© WOC News